减重版司美格鲁肽中国说明书更新，纳入心血管获益结果

Core Viewpoint - The National Medical Products Administration (NMPA) of China has approved an update to the label of Novo Nordisk's semaglutide (2.4mg), indicating cardiovascular benefits based on the SELECT trial results [1] Group 1: Product Update - The updated label for Novo Nordisk's semaglutide includes findings that it can reduce the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes [1]